Text Size

PROSTACOX : Metastatic Prostate Chemotherapy

This study has been completed.
Sponsor:
Information provided by:
University Hospital, Rouen
ClinicalTrials.gov Identifier:
NCT00213694
First received: September 13, 2005
Last updated: March 4, 2013
Last verified: March 2013
History of Changes
  Purpose

Clinical response to chemotherapy. Biological parameter (PSA) and RECIST evaluation. Association of Docetaxel (J 15) and Celecoxib.


Condition Intervention Phase
Metastatic Prostate Cancer
 Drug: docetaxel and celecoxib
 Phase 2

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Efficacy of Docetaxel (J 15) and Celecoxib in Metastatic Prostate Cancer

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University Hospital, Rouen:

Estimated Enrollment: 52
Study Start Date: November 2003
Estimated Study Completion Date: June 2006
Detailed Description:

Association Docetaxel (J 15) and celecoxib Patient survival Biological parameter : PSA Clinical status RECIST evaluation

  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • metastatic prostate cancer
  • ASCO progression criteria

Exclusion Criteria:

  • other prostate chemotherapy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00213694

Locations
France
Charles Nicolle, University Hospital
Rouen, France, 76031
Sponsors and Collaborators
University Hospital, Rouen
Investigators
Principal Investigator: Christian PFISTER, MD, PhD University Hospital, Rouen
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00213694     History of Changes
Other Study ID Numbers: 2003/052/HP
Study First Received: September 13, 2005
Last Updated: March 4, 2013
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Docetaxel
Celecoxib
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Cyclooxygenase 2 Inhibitors
 Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Central Nervous System Agents
Antirheumatic Agents

ClinicalTrials.gov processed this record on May 16, 2013